001     140085
005     20240321220735.0
024 7 _ |a 10.1371/journal.pone.0200602
|2 doi
024 7 _ |a pmid:30011310
|2 pmid
024 7 _ |a pmc:PMC6047809
|2 pmc
024 7 _ |a altmetric:45099024
|2 altmetric
037 _ _ |a DZNE-2020-06407
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Derkow, Katja
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Distinct expression of the neurotoxic microRNA family let-7 in the cerebrospinal fluid of patients with Alzheimer's disease.
260 _ _ |a San Francisco, California, US
|c 2018
|b PLOS
264 _ 1 |3 online
|2 Crossref
|b Public Library of Science (PLoS)
|c 2018-07-16
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1602242867_10993
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a MicroRNAs (miRNAs) are non-coding RNAs originally involved in RNA silencing and post-transcriptional regulation of gene expression. We have shown in previous work that the miRNA let-7b can act as a signalling molecule for Toll-like receptor 7, thereby initiating innate immune pathways and apoptosis in the central nervous system. Here, we investigated whether different members of the miRNA family let-7, abundantly expressed in the brain, are released into the human cerebrospinal fluid (CSF) and whether quantitative differences in let-7 copies exist in neurodegenerative diseases. RNA isolated from CSF of patients with Alzheimer´s disease (AD) and from control patients with frontotemporal lobe dementia (FTLD), major depressive episode (MDE) without clinical or neurobiological signs of AD, and healthy individuals, was reverse transcribed with primers against nine let-7 family members, and miRNAs were quantified and analyzed comparatively by quantitative PCR. let-7 miRNAs were present in CSF from patients with AD, FTLD, MDE, and healthy controls. However, the amount of individual let-7 miRNAs in the CSF varied substantially. CSF from AD patients contained higher amounts of let-7b and let-7e compared to healthy controls, while no differences were observed regarding the other let-7 miRNAs. No increase in let-7b and let-7e was detected in CSF from FTLD patients, while in CSF from MDE patients, let-7b and let-7e copy levels were elevated. In CSF from AD patients, let-7b and let-7e were associated with extracellular vesicles. let-7 family members present in the CSF mediated neurotoxicity in vitro, albeit to a variable extent. Taken together, neurotoxic let-7 miRNAs are differentially and specifically released in AD, but also in MDE patients. Thus, these miRNAs may mirror common neuropathological paths and by this serve to unscramble mechanisms of different neurodegenerative diseases.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
542 _ _ |i 2018-07-16
|2 Crossref
|u http://creativecommons.org/licenses/by/4.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a MicroRNAs
|2 NLM Chemicals
650 _ 7 |a mirnlet7 microRNA, human
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cell-Derived Microparticles: metabolism
|2 MeSH
650 _ 2 |a Depressive Disorder, Major: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Gene Expression Regulation
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a MicroRNAs: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
700 1 _ |a Rössling, Rosa
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Schipke, Carola
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Krüger, Christina
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Bauer, Jakob
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Fähling, Michael
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Stroux, Andrea
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Schott, Eckart
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Ruprecht, Klemens
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 9
|u dzne
700 1 _ |a Lehnardt, Seija
|0 P:(DE-HGF)0
|b 10
|e Corresponding author
773 1 8 |a 10.1371/journal.pone.0200602
|b : Public Library of Science (PLoS), 2018-07-16
|n 7
|p e0200602
|3 journal-article
|2 Crossref
|t PLOS ONE
|v 13
|y 2018
|x 1932-6203
773 _ _ |a 10.1371/journal.pone.0200602
|g Vol. 13, no. 7, p. e0200602 -
|0 PERI:(DE-600)2267670-3
|n 7
|q 13:7|p e0200602
|t PLOS ONE
|v 13
|y 2018
|x 1932-6203
856 4 _ |u https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200602
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047809
856 4 _ |u https://pub.dzne.de/record/140085/files/journal.pone.0200602.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/140085/files/journal.pone.0200602.gif?subformat=icon
|x icon
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/140085/files/journal.pone.0200602.jpg?subformat=icon-1440
|x icon-1440
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/140085/files/journal.pone.0200602.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/140085/files/journal.pone.0200602.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/140085/files/journal.pone.0200602.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:140085
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811024
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2018
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PLOS ONE : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-04-12T10:14:32Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-04-12T10:14:32Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-04-12T10:14:32Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2022-11-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-16
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Coordinator of Clinical Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1811005
980 1 _ |a FullTexts
999 C 5 |9 -- missing cx lookup --
|a 10.1056/NEJMra0909142
|2 Crossref
|o 10.1056/NEJMra0909142
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.tcb.2008.07.007
|2 Crossref
|o 10.1016/j.tcb.2008.07.007
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nmeth.1294
|2 Crossref
|o 10.1038/nmeth.1294
999 C 5 |9 -- missing cx lookup --
|a 10.1373/clinchem.2010.147405
|2 Crossref
|o 10.1373/clinchem.2010.147405
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.jprot.2010.06.006
|2 Crossref
|o 10.1016/j.jprot.2010.06.006
999 C 5 |y 2012
|2 Crossref
|o WJ Lukiw 2012
999 C 5 |9 -- missing cx lookup --
|a 10.1038/ncomms1285
|2 Crossref
|o 10.1038/ncomms1285
999 C 5 |9 -- missing cx lookup --
|a 10.3402/jev.v3.24722
|2 Crossref
|o 10.3402/jev.v3.24722
999 C 5 |9 -- missing cx lookup --
|a 10.3233/JAD-2008-14103
|2 Crossref
|o 10.3233/JAD-2008-14103
999 C 5 |9 -- missing cx lookup --
|a 10.1089/neu.2012.2596
|2 Crossref
|o 10.1089/neu.2012.2596
999 C 5 |9 -- missing cx lookup --
|a 10.1002/jcp.24254
|2 Crossref
|o 10.1002/jcp.24254
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nn.3113
|2 Crossref
|o 10.1038/nn.3113
999 C 5 |9 -- missing cx lookup --
|a 10.1001/jamapsychiatry.2016.0004
|2 Crossref
|o 10.1001/jamapsychiatry.2016.0004
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000210388
|2 Crossref
|o 10.1159/000210388
999 C 5 |9 -- missing cx lookup --
|a 10.3233/JAD-2011-110329
|2 Crossref
|o 10.3233/JAD-2011-110329
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000322588
|2 Crossref
|o 10.1159/000322588
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e3181c47cc2
|2 Crossref
|o 10.1212/WNL.0b013e3181c47cc2
999 C 5 |9 -- missing cx lookup --
|a 10.1182/blood-2010-09-308684
|2 Crossref
|o 10.1182/blood-2010-09-308684
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.ymeth.2010.01.032
|2 Crossref
|o 10.1016/j.ymeth.2010.01.032
999 C 5 |9 -- missing cx lookup --
|a 10.1523/JNEUROSCI.4760-07.2008
|2 Crossref
|o 10.1523/JNEUROSCI.4760-07.2008
999 C 5 |9 -- missing cx lookup --
|a 10.1073/pnas.1432609100
|2 Crossref
|o 10.1073/pnas.1432609100
999 C 5 |9 -- missing cx lookup --
|a 10.1186/gb-2004-5-3-r13
|2 Crossref
|o 10.1186/gb-2004-5-3-r13
999 C 5 |y 2011
|2 Crossref
|o A van Harten 2011
999 C 5 |9 -- missing cx lookup --
|a 10.1038/ncomms3123
|2 Crossref
|o 10.1038/ncomms3123
999 C 5 |9 -- missing cx lookup --
|a 10.1186/1479-5876-10-5
|2 Crossref
|o 10.1186/1479-5876-10-5
999 C 5 |9 -- missing cx lookup --
|a 10.1172/JCI81129
|2 Crossref
|o 10.1172/JCI81129
999 C 5 |9 -- missing cx lookup --
|a 10.1177/1352458507077943
|2 Crossref
|o 10.1177/1352458507077943
999 C 5 |9 -- missing cx lookup --
|a 10.1177/1352458506071196
|2 Crossref
|o 10.1177/1352458506071196
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.neurobiolaging.2013.07.005
|2 Crossref
|o 10.1016/j.neurobiolaging.2013.07.005
999 C 5 |9 -- missing cx lookup --
|a 10.1373/clinchem.2014.224238
|2 Crossref
|o 10.1373/clinchem.2014.224238


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21